Cephalon pays CEO more than hefty rivals

Which drug exec gets paid 140 percent more than the median among his peers? Hint: His company makes the anti-narcolepsy med Provigil. And he made a cool $13.5 million last year (the AP says $16 million). That paycheck included a $1.2 million salary, $2.2 million in bonus, and $10.1 million in stock and options.

If you said Cephalon CEO Frank Baldino (photo), you're correct. Baldino beat out Big Pharma chiefs Jeff Kindler ($9.5 million, according to the WSJ) and Bristol-Myers Squibb's Jim Cornelius ($11.3 million). That's saying something, considering the fact that Cephalon's $1.8 billion in revenues is dwarfed by Pfizer's $48.6 billion and Bristol's $19 billion.

Actually, Baldino qualified for an even bigger bonus, the company said, but its compensation committee decided to shave a bit off the top because of Cephalon's recent $425 million settlement with the U.S. Attorney's office in Philadelphia. The company was under investigation for off-label marketing violations.

- read the item at the WSJ Health Blog
- check out the AP's figures here

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.